

# Inflammation and Hypercoagulability in Anti-neutrophil Cytoplasmic Antibody associated Vasculitis

Citation for published version (APA):

Busch, M. (2024). *Inflammation and Hypercoagulability in Anti-neutrophil Cytoplasmic Antibody associated Vasculitis: Lessons learned from COVID-19*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20240508mb>

**Document status and date:**

Published: 01/01/2024

**DOI:**

[10.26481/dis.20240508mb](https://doi.org/10.26481/dis.20240508mb)

**Document Version:**

Publisher's PDF, also known as Version of record

**Please check the document version of this publication:**

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

**Take down policy**

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

Propositions belonging to the thesis

**Inflammation and Hypercoagulability in Anti-neutrophil Cytoplasmic Antibody associated Vasculitis  
- Lessons learned from COVID-19**

1. A dysregulated immune system, i.e., complement overactivation, is an important driver of the intrinsic coagulation pathway in COVID-19 (this thesis).
2. Hypercoagulability in COVID-19 is associated with adverse clinical outcomes in patients with severe COVID-19 (this thesis).
3. Complement 5a inhibition is safe and effective in preventing a severe course of disease in COVID-19 (this thesis).
4. Resolving mediators of inflammation (i.e., Annexin A1) are novel promising targets in infectious and auto-immune diseases (this thesis).
5. A key lesson from COVID-19 is that infectious diseases offer valuable insights into the intricate relationship between the immune and coagulation systems. These insights can enhance our understanding of various other diseases (this thesis).
6. With striking homology to COVID-19, hypercoagulability is associated with activation of the intrinsic coagulation pathway and most likely driven by a dysregulated immune response in AAV (this thesis).
7. Inhibitors of the intrinsic coagulation pathway or C5a inhibition are potentially therapeutic targets to reduce the risk of (micro)thrombotic events in AAV (this thesis).
8. SARS-CoV-2 is the trigger but hyperinflammation is the bullet in severe COVID-19.
9. The pandemic forced human mankind for a short moment in time to collectively share a common interest across the globe.
10. Never let a good crisis go to waste (Winston Churchill).

Matthias H. Busch